← Leaderboards
Michelle E Ehrlich
University Of Pennsylvania
$23,154,112
Attributed
$63,851,610
Total exposure
20
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $12.4M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$63,851,610 · 20
By mechanism
U01$25,534,922 · 1
R01$22,545,353 · 9
RF1$12,381,388 · 3
R21$1,302,296 · 4
P01$1,243,539 · 2
R56$844,112 · 1
Top collaborators
- Bin Zhang30 shared
- Vahram Haroutunian25 shared
- Samuel E Gandy23 shared
- Scott Allen Noggle20 shared
- Eric E Schadt20 shared
- Koichi Iijima11 shared
- Jun Zhu11 shared
- Stephen R Salton10 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposMolecularGenesNeuronsBrainS DiseaseMouse ModelBrain RegionCellsS Disease ModelPathway InteractionsProteinsGeneticNetwork ModelsBehaviorPhenotypeData SetMolecular ProfilingGenomicsPathway AnalysisBiologyMolecular ScaleGene ExpressionTranscriptome Sequencing
Grant awards (73)
Novel directions for investigating the role of VGF in comorbid Major Depressive Disorder and Alzheimer's disease$844,931
R01 · FY2025 · AG
Intranasal delivery of VGF-derived peptides in a preclinical model of Alzheimer's disease$827,826
R01 · FY2025 · AG
Intranasal delivery of VGF-derived peptides in a preclinical model of Alzheimer's disease$844,721
R01 · FY2024 · AG
Neonatal Opioid Exposure and Withdrawal: Molecular and Behavioral Consequences$696,506
R01 · FY2024 · DA
Neonatal Opioid Exposure and Withdrawal: Molecular and Behavioral Consequences$696,506
R01 · FY2023 · DA
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's Disease$2,272,422
U01 · FY2022 · AG
Systems modeling of shared and distinct molecular mechanisms underlying comorbid Major Depressive Disorder and Alzheimer's disease$842,983
R01 · FY2022 · AG
Neonatal Opioid Exposure and Withdrawal: Molecular and Behavioral Consequences$696,506
R01 · FY2022 · DA
Neonatal Opioid Exposure and Withdrawal: Molecular and Behavioral Consequences$82,448
R01 · FY2022 · DA
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's Disease$1,848,040
U01 · FY2021 · AG
Integrative Network Modeling of Cognitive Resilience to Alzheimer's Disease$1,211,963
R01 · FY2021 · AG
Systems modeling of shared and distinct molecular mechanisms underlying comorbid Major Depressive Disorder and Alzheimer's disease$984,151
R01 · FY2021 · AG
Neonatal Opioid Exposure and Withdrawal: Molecular and Behavioral Consequences$712,968
R01 · FY2021 · DA
Identification and characterization of receptors targeting VGF-derived peptides.$169,500
U01 · FY2021 · AG
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's Disease$3,115,604
U01 · FY2020 · AG
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's Disease$1,265,373
U01 · FY2020 · AG
Integrative Network Modeling of Cognitive Resilience to Alzheimer's Disease$1,224,616
R01 · FY2020 · AG
Systems modeling of shared and distinct molecular mechanisms underlying comorbid Major Depressive Disorder and Alzheimer's disease$842,983
R01 · FY2020 · AG
Neonatal Opioid Exposure and Withdrawal: Molecular and Behavioral Consequences$710,780
R01 · FY2020 · DA
Systems modeling of shared and distinct molecular mechanisms underlying comorbid Major Depressive Disorder and Alzheimer's disease$282,334
R01 · FY2020 · AG
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's Disease$164,076
U01 · FY2020 · AG
Integrated understanding of complex viral network biology in Alzheimer's Disease$4,111,077
RF1 · FY2019 · AG · contact PI
VGF peptide TLQP-21, a novel microglial C3aR1 modulator in Alzheimer's disease$4,083,855
RF1 · FY2019 · AG
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's Disease$1,691,295
U01 · FY2019 · AG
Integrative Network Modeling of Cognitive Resilience to Alzheimer's Disease$1,248,971
R01 · FY2019 · AG
Systems modeling of shared and distinct molecular mechanisms underlying comorbid Major Depressive Disorder and Alzheimer's disease$843,557
R01 · FY2019 · AG
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's Disease$423,750
U01 · FY2019 · AG
SYSTEMATIC DRUG REPURPOSING TARGETING IMMUNE ACTIVATION NETWORKS IN ALZHEIMER'S DISEASE (AD)$4,186,456
RF1 · FY2018 · AG
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's Disease$1,708,836
U01 · FY2018 · AG
Integrative Network Modeling of Cognitive Resilience to Alzheimer's Disease$1,263,645
R01 · FY2018 · AG
Systems modeling of shared and distinct molecular mechanisms underlying comorbid Major Depressive Disorder and Alzheimer's disease$867,487
R01 · FY2018 · AG
Integrative Biology Approach to Complexity of Alzheimer's Disease$2,699,009
U01 · FY2017 · AG
Integrative Network Modeling of Cognitive Resilience to Alzheimer's Disease$1,322,834
R01 · FY2017 · AG
Integrated understanding of complex viral network biology in Alzheimer's Disease$844,112
R56 · FY2017 · AG
Dopamine D1 Receptor in mouse models of primary dystonia$489,956
R01 · FY2017 · NS · contact PI
Integrative Biology Approach to Complexity of Alzheimer's Disease$169,498
U01 · FY2017 · AG
Integrative Biology Approach to Complexity of Alzheimer's Disease$3,281,179
U01 · FY2016 · AG
Integrative Biology Approach to Complexity of Alzheimer's Disease$1,139,520
U01 · FY2016 · AG
Dopamine D1 Receptor in mouse models of primary dystonia$489,958
R01 · FY2016 · NS · contact PI
Integrative Biology Approach to Complexity of Alzheimer's Disease$168,108
U01 · FY2016 · AG
Integrative Biology Approach to Complexity of Alzheimer's Disease$1,702,824
U01 · FY2015 · AG
Dopamine D1 Receptor in mouse models of primary dystonia$508,137
R01 · FY2015 · NS · contact PI
Integrative Biology Approach to Complexity of Alzheimer's Disease$111,000
U01 · FY2015 · AG
Integrative Biology Approach to Complexity of Alzheimer's Disease$96,335
U01 · FY2015 · AG
Integrative Biology Approach to Complexity of Alzheimer's Disease$1,734,746
U01 · FY2014 · AG
Dopamine D1 Receptor in mouse models of primary dystonia$501,180
R01 · FY2014 · NS · contact PI
Accelerating Medicine Partnership in Alzheimer's Disease: Enabling collaborative$114,059
U01 · FY2014 · AG
Integrative Biology Approach to Complexity of Alzheimer's Disease$1,659,748
U01 · FY2013 · AG
Dopamine D1 Receptor in mouse models of primary dystonia$505,438
R01 · FY2013 · NS · contact PI
Huntington's Disease and the Striatum$423,750
R01 · FY2010 · NS · contact PI
Huntington's Disease and the Striatum$423,750
R01 · FY2009 · NS · contact PI
CORE--MOLECULAR NEUROSCIENCE$279,282
P01 · FY2009 · AG · contact PI
Post-Synaptic Striatal TrkB: Role in the Response to Cocaine$204,075
R21 · FY2009 · DA · contact PI
Molecular Regulation of a Striatal DARPP-32 Phenotype$334,491
R01 · FY2008 · NS · contact PI
CORE--MOLECULAR NEUROSCIENCE$307,001
P01 · FY2008 · AG · contact PI
Post-Synaptic Striatal TrkB: Role in the Response to Cocaine$263,825
R21 · FY2008 · DA · contact PI
CORE--MOLECULAR NEUROSCIENCE$310,905
P01 · FY2007 · AG · contact PI
Molecular Regulation of a Striatal DARPP-32 Phenotype$307,850
R01 · FY2007 · NS · contact PI
Molecular Regulation of a Striatal DARPP-32 Phenotype$317,045
R01 · FY2006 · NS · contact PI
CORE--MOLECULAR NEUROSCIENCE$222,223
P01 · FY2006 · AG · contact PI
Molecular Regulation of a Striatal DARPP-32 Phenotype$324,675
R01 · FY2005 · NS
Buprenorphine Treatment of Neonatal Abstinence Syndrome$254,884
R21 · FY2005 · DA
Huntington's Disease and the Striatum$216,450
R21 · FY2005 · NS
Basal Ganglia Expression of TorsinA in Transgenic Mice$181,531
R21 · FY2005 · NS
CORE--MOLECULAR NEUROSCIENCE$124,128
P01 · FY2005 · AG
Basal Ganglia Expression of TorsinA in Transgenic Mice$181,531
R21 · FY2004 · NS
ONTOGENY OF NEUROADAPTIVE RESPONSES TO PSYCHOSTIMULANTS$310,500
R01 · FY2002 · NS
Regulation of Beta amyloidogenesis--Animal Models$0
P01 · FY2002 · AG
ONTOGENY OF NEUROADAPTIVE RESPONSES TO PSYCHOSTIMULANTS$255,396
R01 · FY2001 · NS
ONTOGENY OF NEUROADAPTIVE RESPONSES TO PSYCHOSTIMULANTS$50,000
R01 · FY2001 · NS
Regulation of Beta amyloidogenesis--Animal Models$0
P01 · FY2001 · AG
ONTOGENY OF NEUROADAPTIVE RESPONSES TO PSYCHOSTIMULANTS$254,511
R01 · FY2000 · NS
Regulation of Beta amyloidogenesis--Animal Models$0
P01 · FY2000 · AG